As of January 29, 2024, UBS analyst Colin Bristow has reiterated a Neutral rating on Amgen (NASDAQ: AMGN) with a revised price target of $314, slightly lower than the previous projection of $315. Bristow’s evaluation takes into account the company’s performance and prevailing market conditions. It is crucial for investors to weigh multiple analysts’ perspectives and conduct thorough research before making any investment choices.
AMGN Stock Shows Positive Price Momentum and Potential for Further Growth in 2024
On January 29, 2024, AMGN stock traded near the top of its 52-week range and above its 200-day simple moving average, indicating positive price momentum. The stock experienced a rise of $1.44 since the market last closed, suggesting investor interest and driving its value higher. AMGN stock opened at $310.81, slightly lower than its previous close, but quickly regained momentum and continued to rise throughout the trading day. This performance over the past year, along with its position above the 200-day moving average, suggests potential for further growth.
Amgen (AMGN) Demonstrates Strong Financial Performance with Growing Net Income and EPS
On January 29, 2024, Amgen (AMGN) showcased a steady and promising performance. The company’s total revenue remained flat at $26.09 billion for the year and $6.87 billion for the third quarter. However, Amgen’s net income and earnings per share (EPS) exhibited significant growth. Net income for the year reached $6.55 billion, a 11.18% increase compared to the previous year. Net income for the third quarter stood at $1.73 billion, a 25.45% increase compared to the previous quarter. EPS rose to $12.11 for the year, a 17.76% increase compared to the previous year. EPS for the third quarter reached $3.22, a 25.22% increase compared to the previous quarter. Amgen’s profitability has improved, and investors may find confidence in the company’s ability to generate strong returns and continue its growth in the pharmaceutical industry.
